Searchable abstracts of presentations at key conferences on calcified tissues

Bone Abstracts

Published by BioScientifica

Page 1 of about 5 results

ba0001op18 | Clinical | ECTS2013

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate- a randomized placebo-controlled trial

Chapurlat Roland , De Villiers Tobias , Bonnick Sydney , Odio Alberto , Palacios Santiago , Scott Boyd , De Tilleghem Celine Le Bailly , DaSilva Carolyn , Leung Albert , Gurner Deborah

see PP446....
0 shares

ba0001pp436 | Osteoporosis: treatment | ECTS2013

Bone mineral density changes in patients with prior fracture suboptimally treated with a bisphosphonate: results from denosumab (DMAb)/ibandronate and DMAb/risedronate trials

Recknor Christopher , Roux Christian , Ho Pei-Ran , Hall Jesse , Bone Henry , Bonnick Sydney , van den Bergh Joop , Ferreira Irene , Wagman Rachel , Brown Jacques P

: In osteoporosis, poor adherence to bisphosphonate (BP) therapy is common, and is associated with poor outcomes and increased treatment costs (Siris 2006; Recker 2005). Although compliance is improved with monthly vs weekly dosing (Reginster 2008), no evidence suggests cycling through BP agents offers therapeutic benefit, assessed by bone mineral density (BMD). In two randomized, open-label studies in postmenopausal women aged ≥55 years previously treated with, but subo...
0 shares

ba0001pp446 | Osteoporosis: treatment | ECTS2013

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate– a randomized placebo-controlled trial

Chapurlat Roland , De Villiers Tobias , Bonnick Sydney , Odio Alberto , Palacios Santiago , Scott Boyd , De Tilleghem Celine Le Bailly , DaSilva Carolyn , Leung Albert , Gurner Deborah

Odanacatib (ODN) is an orally-active cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This study evaluated the effects of ODN 50mg once weekly on BMD, bone turnover markers and safety in patients previously treated with alendronate (ALN).This was a randomized, double-blind, placebo-controlled, 24-month study. The primary endpoint was % change from baseline at month 24 of femoral neck (FN) BMD. Postmenopausal women (...
0 shares

ba0003OP7 | Clinical | ECTS2014

In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

Brown Jacques P , Bolognese Michael A , Ho Pei-Ran , Roux Christian , Bone Henry G , Bonnick Sydney L , van den Bergh Joop , Ferreira Irene , Ghelani Prayashi , Dakin Paula , Wagman Rachel B , Recknor Christopher

see PP357....
0 shares

ba0003pp357 | Osteoporosis: treatment | ECTS2014

In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

Brown Jacques P , Bolognese Michael A , Ho Pei-Ran , Roux Christian , Bone Henry G , Bonnick Sydney L , van den Bergh Joop , Ferreira Irene , Ghelani Prayashi , Dakin Paula , Wagman Rachel B , Recknor Christopher

Low bone mineral density (BMD) is an important and modifiable risk factor for fracture in postmenopausal women with osteoporosis. Denosumab (DMAb) shows a stronger relationship between BMD increases and antifracture efficacy than oral bisphosphonate (BP) therapies. Subjects who remain at higher risk of fracture despite current BP therapy need treatment. In two studies, DMAb significantly increased BMD and decreased bone turnover markers vs a BP (ibandronate (IBN) or risedronat...
0 shares

Published by BioScientifica

Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more